La radiologia medica

, Volume 117, Issue 3, pp 426–444 | Cite as

Endovascular radiofrequency renal denervation in treating refractory arterial hypertension: a preliminary experience

  • G. Simonetti
  • A. Spinelli
  • R. Gandini
  • V. Da Ros
  • E. Gaspari
  • I. Coco
  • M. De Francesco
  • D. Santucci
  • N. Di Daniele
  • R. Lauro
Vascular and Interventional Radiology / Radiologia Vascolare e Interventistica

Abstract

Purpose

This study was done to investigate the efficacy and safety of percutaneous renal denervation with the Symplicity catheter for reducing blood pressure in patients with essential hypertension resistant to medical therapy (systolic blood pressure >160 mmHg despite the use of three or more antihypertensive drugs, including a diuretic).

Materials and methods

In September 2010, five patients affected by essential hypertension resistant to medical therapy were treated. All patients were studied by computed tomography angiography (CTA) of the renal arteries before the procedure and underwent follow-up at 30 and 60 days with colour Doppler ultrasound (CDUS) with evaluation of resistive index, glomerular filtration rate (GFR), 24-h blood pressure and serum catecholamine concentration. Student’s t test was used to assess the effectiveness of the procedure in lowering blood pressure.

Results

In treated patients, mean blood pressure at baseline was 171/100 mmHg [standard deviation (SD)±8/10]; mean GFR was 91.6 ml/min/1.73 m2 (SD±15). Blood pressure after the procedure was reduced by −18/−5 and −13/−10 mmHg at 30 and 60 days, respectively, with a mean medication reduction of 3.6. No complications occurred during the intra- or periprocedural period or during short-term follow-up.

Conclusions

The Symplicity system proved to be efficacious and without serious adverse events in reducing blood pressure and antihypertensive medication use in patients affected by essential hypertension resistant to medical therapy. Although encouraging, our data are preliminary and need to be validated by larger prospective randomised studies.

Keywords

Percutaneous renal denervation Essential hypertension Medical-therapy-resistant 

Sistema di denervazione renale endovascolare a radiofrequenza nel trattamento dell’ipertensione arteriosa resistente a terapia farmacologica: esperienza preliminare

Riassunto

Obiettivo

Scopo del presente studio è stato valutare l’efficacia e la sicurezza della procedura di simpaticectomia renale percutanea a radiofrequenza mediante catetere Symplicity nel ridurre la pressione arteriosa sistemica in pazienti con ipertensione essenziale resistenti alla terapia farmacologica convenzionale (pressione sistolica>160 mmHg con 3 o più farmaci antiipertensivi, incluso diuretico).

Materiali e metodi

Nel mese di settembre 2010, sono stati trattati 5 pazienti affetti da ipertensione arteriosa essenziale non rispondenti a terapia. È stata eseguita angio-tomografia computerizzata (TC) delle arterie renali pre-procedurale e follow-up a 30 e 60 giorni con eco-color Doppler, valutazione degli indici di resistenza, del filtrato glomerulare, monitoraggio della pressione arteriosa nelle 24 ore e misurazione della catecolaminemia. L’analisi dei dati è stata effettuata mediante il test t di Student.

Risultati

I valori pressori medi basali della popolazione erano 171/100 mmHg [deviazione standard (DS)±8/10], con filtrato glomerulare medio di 91,6 ml/min/1,73 m2 (DS±15). Il decremento pressorio medio post-procedurale è stato di −18/−5 mmHg e −13/−10 mmHg a 30 e 60 giorni con riduzione media di 3,6 farmaci. Non vi sono state complicanze intra-/peri-procedurali e nel successivo follow-up a breve termine.

Conclusioni

Il sistema Symplicity si è dimostrato efficace nel ridurre i livelli pressori e la somministrazione dei farmaci anti-ipertensivi, in assenza di evidenti eventi avversi. Nonostante incoraggianti premesse, sarà necessario validare i preliminari dati ottenuti mediante più ampi studi prospettici randomizzati.

Parole chiave

Simpaticectomia renale percutanea Ipertensione essenziale Resistenza a terapia farmacologica 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References/Bibliografia

  1. 1.
    Lloyd-Jones D, Adams R, Carnethon M et al (2009) Heart disease and stroke statistics — 2009 update: a report from the American Heart Association Statistics Committee and stroke Statistics Subcommittee. Circulation 119:480–486PubMedCrossRefGoogle Scholar
  2. 2.
    Calhoun DA, Jones D, Textor S et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional research. Hypertension 51:1403–1419Google Scholar
  3. 3.
    Pisoni R, Ahmed MI, Calhoun DA (2009) Characterization and treatment of resistant hypertension. Curr Cardiol Rep 11:407–413PubMedCrossRefGoogle Scholar
  4. 4.
    Armario P, Oliveras A, Hernàndez Del Rey R et al (2009) Prevalence of target organ damage and factors associated with cardiovascular events in subjects with refractory hypertension. Med Clin (Barc) 133:127–131CrossRefGoogle Scholar
  5. 5.
    Morissey DM, Brookes VS, Cooke WT (1953) Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1:403–408CrossRefGoogle Scholar
  6. 6.
    Schlaich MP, Socratous F, Hennebry S et al (2009) Sympathetic activation in chronic renal failure. J Am Soc Nephrol 20:933–939PubMedCrossRefGoogle Scholar
  7. 7.
    Malpas SC (2009) Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 90:513–557CrossRefGoogle Scholar
  8. 8.
    Mancia G, Bousquet P, Elghozi JL et al (2007) The sympathetic nervous system and the metabolic syndrome. J Hypertens 25:909–920PubMedCrossRefGoogle Scholar
  9. 9.
    Barajas L, Liu L, Powers K (1992) Anatomy of the renal innervations: intrarenal aspects and ganglia of origin. Can J Physiol Pharmacol 70:735–749PubMedCrossRefGoogle Scholar
  10. 10.
    Moss N (1982) Renal function and renal afferent and efferent nerve activity. Am J Physiol 243:F425–F433PubMedGoogle Scholar
  11. 11.
    Di Bona GF, Sawin LL, Jones SY (1996) Characteristics of renal sympathetic nerve activity in sodiumretaining disorders. Am J Physiol 271:R295–R302Google Scholar
  12. 12.
    Burck SL, Evans RG, Head GA (2010) Effects of chronic sympathoinhibition on reflex control of renal blood flow and plasma rennin activity in renovascular hypertension. Br J Pharmacol 159:438–448CrossRefGoogle Scholar
  13. 13.
    Di Bona GF (2000) Nervous kidney interaction between renal sympathetic nerves and the renin-angiotensin system in the control of renal function. Hypertension 36:1083–1088Google Scholar
  14. 14.
    Kopp UC, Jones Sy, Di Bona GF (2008) Afferent renal denervation impairs baro reflex control of efferent renal sympathetic nerve activity. Am J Physiol Regul Integr Comp Physiol 295:1882–1890CrossRefGoogle Scholar
  15. 15.
    Ciriello J, de Oliveira CV (2002) Renal afferents and hypertension. Curr Hypertens Rep 4:136–142PubMedCrossRefGoogle Scholar
  16. 16.
    Schlaich MP, Sobotka AP, Krum H et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932–934PubMedCrossRefGoogle Scholar
  17. 17.
    Schlaich MP, Sobotka AP, Krum H et al (2009) Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 54:1195–1201PubMedCrossRefGoogle Scholar
  18. 18.
    Fajardo J, Lopez-Novoa JM et al (1986) Effect of chemical sympathectomy on renal hydroelectrolytic handling in dogs with chronic caval constriction. Clin Physiol Biochem 4:252–256PubMedGoogle Scholar
  19. 19.
    le Noble JL, Janssen BJ, Lappe RW et al (1985) Pharmacological evidence for rapid destruction of efferent renal nerves in rats by intrarenal infusion of 6-hydroxydopamine. J Hypertension 38(Suppl): S137–S140Google Scholar
  20. 20.
    Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRefGoogle Scholar
  21. 21.
    Schlaich MP, Sobotka AP, Krum H et al (2009) Renal sympathetic nerve ablation for the treatment of uncontrolled hypertension. N Engl J Med 361:932–934PubMedCrossRefGoogle Scholar
  22. 22.
    Fagius J (2003) Sympathetic nerve activity in metabolic control-some basic concepts. Acta Physiol Scand 177:337–343PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • G. Simonetti
    • 1
  • A. Spinelli
    • 1
  • R. Gandini
    • 1
  • V. Da Ros
    • 1
  • E. Gaspari
    • 1
  • I. Coco
    • 1
  • M. De Francesco
    • 2
  • D. Santucci
    • 2
  • N. Di Daniele
    • 2
  • R. Lauro
    • 2
  1. 1.Dipartimento di Diagnostica per Immagini, Imaging Molecolare, Radiologia Interventistica e RadioterapiaFondazione Policlinico Universitario “ Tor Vergata ”RomaItaly
  2. 2.Unità di Nefrologia, Dipartimento di Medicina InternaFondazione Policlinico Universitario “ Tor Vergata ”RomaItaly

Personalised recommendations